Cargando…

EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy

Detalles Bibliográficos
Autores principales:	Piccolo, F, Tosh, J, De Boisvilliers, S, Patel, S, Patel, V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747461/ http://dx.doi.org/10.1016/j.jval.2022.09.710

Ejemplares similares

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
por: Zaqout, Ahmed, et al.
Publicado: (2022)

Sotrovimab: is it effective in early treatment of mild and moderate COVID-19 infections? A retrospective study
por: Elesdoudy, Ahmed
Publicado: (2021)

518. Comparable Outcomes of Remdesivir and Sotrovimab among High-risk Patients with Mild to Moderate COVID-19 During the Omicron BA.1 Surge
por: Chesdachai, Supavit, et al.
Publicado: (2023)

1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab
por: Agostini, Maria L, et al.
Publicado: (2022)

Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022)

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir
por: Martin-Blondel, Guillaume, et al.
Publicado: (2023)

Clinical Outcomes of Sotrovimab Treatment in 10 High-Risk Patients with Mild COVID-19: A Case Series
por: Takeda, Kenichiro, et al.
Publicado: (2022)

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
por: Moya, Jaynier, et al.
Publicado: (2023)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19
por: Sager, Jennifer E., et al.
Publicado: (2023)

EE422 Healthcare Costs Associated with Severe VS Moderate and Mild COVID-19 - a US Payer Perspective
por: Holy, C, et al.
Publicado: (2022)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

Poster Sessions 292 - 465
Publicado: (2003)

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
por: Birk, Navina K, et al.
Publicado: (2022)

1154. Safety, Tolerability, and Viral Pharmacodynamics of the IgG Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection for the Treatment of Early Mild-to-Moderate COVID-19
por: Gupta, Anil K, et al.
Publicado: (2022)

1145. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 in the US
por: Cheng, Mindy M, et al.
Publicado: (2022)

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022)

465. Risk Factors Associated with Critical COVID-19 Requiring Mechanical Ventilation
por: Chris, Robert B, et al.
Publicado: (2020)

Fatigue Limit of Custom 465 with Surface Strengthening Treatment
por: An, Gang, et al.
Publicado: (2020)

P465 Aspergillosis in free-ranging Magellanic penguins
por: Trápaga, Mariana, et al.
Publicado: (2022)

Sotrovimab: Emergence of acquired resistance: 4 case reports
Publicado: (2022)

The FCC-ee study: Progress and challenges
por: Koratzinos, Michael, et al.
Publicado: (2015)

465 Skeeter Syndrome, a Case Report and Literature Review
por: Garcia-Calderin, Diego, et al.
Publicado: (2012)

Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients
por: Villanego, Florentino, et al.
Publicado: (2022)

EE468 Healthcare Resource Utilisation and Costs Associated With the Management of Hospitalised COVID-19 Patients in England
por: Patel, V, et al.
Publicado: (2022)

Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle Glaucoma in Italy
por: Fea, Antonio Maria, et al.
Publicado: (2021)

Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection
por: Gupta, Isha, et al.
Publicado: (2022)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Azithromycin for mild-to-moderate COVID-19
por: Patel, Jigar, et al.
Publicado: (2021)

Genome Sequence of a Thermophilic Bacillus, Geobacillus thermodenitrificans DSM465
por: Yao, Nana, et al.
Publicado: (2013)

Identification of Ser465 as a novel PINK1 autophosphorylation site
por: Guo, Ji-feng, et al.
Publicado: (2017)

465. Microbial Removal Efficacy of a Novel Nonantimicrobial Hand Soap
por: Edmonds-Wilson, Sarah, et al.
Publicado: (2018)

465. Mental Health Treatment Disparities During the COVID-19 Pandemic
por: Kricorian, Katherine, et al.
Publicado: (2021)

Measurement of the cross-section for the process $ee \to ee\gamma^{*}\gamma^{*} \to eeX$ at $\sqrt{S_{ee}}$ = 189 GeV
por: Przybycien, M B
Publicado: (2000)

Minimally Invasive Surgery in Mild-to-Moderate Glaucoma Patients in Italy: Is It Time to Change?
por: Costagliola, Ciro, et al.
Publicado: (2020)

Moderate and severe plaque psoriasis: cost-of-illness study in Italy
por: Colombo, GL, et al.
Publicado: (2008)

Measurement of the Cross-Section for the Process ee-ee gamma*gamma*-eeX at sqrt(s_ee) = 189 GeV
por: CERN. Geneva
Publicado: (1999)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

Clinical events and echocardiographic lesion progression rate in subjects with mild or moderate aortic regurgitation
por: Badiani, Sveeta, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3rtt7ouui2uusme5iodkl396i8